{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:28:15Z","timestamp":1789504095837,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009403","name":"Menofia\u00a0University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108952","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T16:01:01Z","timestamp":1756828861000},"page":"108952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design, synthesis, biological and computational evaluation of novel S\/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy"],"prefix":"10.1016","volume":"165","author":[{"given":"Ibrahim M.","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel A.-H.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108952_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108952_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108952_bb0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/35077213","article-title":"Proliferation, cell cycle and apoptosis in cancer","volume":"411","author":"Evan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108952_bb0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108952_bb0025","first-page":"298","article-title":"Small molecule cyclin-dependent kinase modulators","volume":"17","author":"Senderowicz","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108952_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","article-title":"G1 phase progression: cycling on cue","volume":"79","author":"Sherr","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108952_bb0035","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nrm2510","article-title":"Cyclin-dependent kinases and cell-cycle transitions: does one fit all?","volume":"9","author":"Hochegger","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0040","first-page":"4100","article-title":"Overexpression of cyclin E in human breast carcinomas","volume":"58","author":"Kim","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108952_bb0045","first-page":"4706","article-title":"Cyclin E is a prognostic marker for ovarian cancer","volume":"9","author":"Yasmeen","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108952_bb0050","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0055","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.108952_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0165-6147(02)02071-0","article-title":"Pharmacological inhibitors of cyclin-dependent kinases","volume":"23","author":"Knockaert","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2025.108952_bb0070","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3390\/cancers6042224","article-title":"Highlights of the latest advances in research on CDK inhibitors","volume":"6","author":"Cicenas","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.108952_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur. J. Biochem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108952_bb0080","first-page":"2445","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108952_bb0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Clinical and pharmacological development of the cyclin-dependent kinase inhibitor flavopiridol","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108952_bb0090","first-page":"3255","article-title":"AT7519, a novel cyclin-dependent kinase inhibitor, inhibits tumor growth in preclinical models","volume":"8","author":"Squires","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108952_bb0095","first-page":"2911","article-title":"PHA-793887, a novel cyclin-dependent kinase inhibitor, is a potent, orally available, and selective antitumor agent","volume":"8","author":"Brasca","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108952_bb0100","first-page":"345","article-title":"The chemistry of 1,2,4-triazolo[1,5-a]pyrimidines","volume":"40","author":"Elgemeie","year":"2003","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0105","first-page":"1355","article-title":"Recent advances in the chemistry and biological activity of [1,2,4]triazolo[1,5-a]pyrimidines","volume":"18","author":"Gomaa","year":"2018","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108952_bb0115","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.drudis.2018.01.035","article-title":"Progress with covalent small-molecule kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108952_bb0120","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.bmcl.2018.05.020","article-title":"Synthesis, characterization and cytotoxicity studies of 1,2,3-triazoles and 1,2,4-triazolo[1,5-a]pyrimidines in human breast cancer cells","volume":"28","author":"Gilandoust","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108952_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105687","article-title":"Design, synthesis, biological assessment, and in-silico studies of 1,2,4-triazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors","volume":"121","author":"Mohamed","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113449","article-title":"Discovery of highly potent tubulin polymerization inhibitors: design, synthesis, and structure\u2013activity relationships of novel 2,7-diaryl [1,2,4]triazolo[1,5-a]pyrimidines","volume":"220","author":"Huo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0135","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ejmech.2016.10.021","article-title":"Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1\/KDM1A) inhibitors","volume":"125","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0140","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.bmcl.2005.11.048","article-title":"Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR","volume":"16","author":"Richardson","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108952_bb0145","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.3390\/molecules27154996","article-title":"Design, synthesis and biological evaluation of novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential CDK2 inhibitors","volume":"27","author":"Yu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108952_bb0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11523-017-0541-2","article-title":"Inhibiting CDK in cancer therapy: current evidence and future directions","volume":"13","author":"Vijayaraghavan","year":"2018","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108952_bb0160","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.ejmech.2009.02.012","article-title":"Synthesis and antiviral evaluation of some new [1,2,4]triazolo[1,5-a]pyrimidine derivatives","volume":"44","author":"Rashad","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0165","first-page":"8349","article-title":"Synthesis and anticancer activity of some novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives","volume":"18","author":"Al-Issa","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108952_bb0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.108952_bb0175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/acs.chemrestox.6b00043","article-title":"Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space","volume":"29","author":"Meanwell","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0180","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-5-70","article-title":"Targeted drug delivery for cancer therapy: the other side of antibodies","volume":"5","author":"Firer","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0190","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.drudis.2012.03.002","article-title":"Cell-penetrating peptides: classes, mechanism of internalization, and therapeutic applications","volume":"17","author":"Milletti","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108952_bb0195","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejmech.2015.01.014","article-title":"Peptide therapeutics: targeting the undruggable space","volume":"94","author":"Tsomaia","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108952_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115603","article-title":"Recent advances in 1,2,3- and 1,2,4-triazole hybrids as antimicrobials and their SAR: a critical review","volume":"259","author":"Tian","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0220","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108952_bb0225","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs\u2014from serendipity to rational design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2025.108952_bb0230","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4155\/fmc.14.50","article-title":"Conformational restriction: an effective tactic in 'follow-on'-based drug discovery","volume":"6","author":"Fang","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0235","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.bmcl.2008.08.079","article-title":"Isoxazole-based inhibitors of cyclin-dependent kinase 2","volume":"18","author":"Tong","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108952_bb0240","article-title":"The development of Cdc25B phosphatase inhibitors","volume":"187","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0245","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1016\/j.bmcl.2013.08.009","article-title":"Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics","volume":"23","author":"Zhao","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108952_bb0250","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0255","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.drudis.2009.07.014","article-title":"The impact of aromatic ring count on compound developability \u2013 are too many aromatic rings a liability in drug design?","volume":"14","author":"Ritchie","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108952_bb0260","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0265","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drudis.2010.11.014","article-title":"The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types","volume":"16","author":"Ritchie","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108952_bb0270","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108952_bb0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.108952_bb0280","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0285","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The current state of peptide drug discovery: back to the future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0290","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108952_bb0295","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2025.108952_bb0300","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108952_bb0305","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.molmed.2015.06.005","article-title":"Cell-penetrating peptides: strategies for anticancer treatment","volume":"21","author":"Raucher","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108952_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2025.108952_bb0315","first-page":"22","article-title":"Cell-penetrating peptides: design strategies beyond primary structure and amphipathicity","volume":"2017","author":"Kalafatovic","year":"1929","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108952_bb0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic peptide therapeutics: past, present and future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0325","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/acs.biochem.6b00226","article-title":"Discovery and mechanism of highly efficient cyclic cell-penetrating peptides","volume":"55","author":"Qian","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2025.108952_bb0330","doi-asserted-by":"crossref","first-page":"11569","DOI":"10.3390\/molecules200611569","article-title":"Surfing the protein-protein interaction surface using docking methods: application to the design of PPI inhibitors","volume":"20","author":"Sable","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108952_bb0335","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing toward the reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108952_bb0340","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1021\/jo01069a030","article-title":"The synthesis of 3\u2032,6-dimethyl-1,2-benzanthracene","volume":"26","author":"Newman","year":"1961","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0345","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3987\/COM-11-12175","article-title":"Feasible synthesis of antagonist of GPR40 by constructing 2-thiouracil ring via acid mediated cyclization","volume":"83","author":"Zhao","year":"2011","journal-title":"Heterocycles"},{"key":"10.1016\/j.bioorg.2025.108952_bb0350","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/cber.190203503125","article-title":"\u00dcber Hydrazide und Azide der Fetts\u00e4uren","volume":"35","author":"Curtius","year":"1902","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"10.1016\/j.bioorg.2025.108952_bb0355","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00706-007-0643-0","article-title":"Synthesis and reactions of some new thiazolo[3,2-a]pyrimidine derivatives","volume":"138","author":"Ali","year":"2007","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.bioorg.2025.108952_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103336","article-title":"Protocol for simultaneous detection of mRNAs and (phospho-)proteins with ARTseq-FISH in mouse embryonic stem cells","volume":"5","author":"Hu","year":"2024","journal-title":"STAR Protoc."},{"key":"10.1016\/j.bioorg.2025.108952_bb0365","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1038\/s41467-024-52055-5","article-title":"Leveraging multiple data types for improved compound-kinase bioactivity prediction","volume":"15","author":"Theisen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108952_bb0370","series-title":"Advanced Cell and Molecular Techniques","first-page":"195","article-title":"Flow cytometry protocols for assessing membrane integrity, cell cycle, and apoptosis in treated cells","author":"Arunachalam","year":"2025"},{"key":"10.1016\/j.bioorg.2025.108952_bb0375","doi-asserted-by":"crossref","DOI":"10.1039\/D5SC02460A","article-title":"A straightforward method for measuring binding affinities of ligands to proteins of unknown concentration in biological tissues","author":"Yan","year":"2025","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2025.108952_bb0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s44386-025-00005-6","article-title":"FeatureDock for protein-ligand docking guided by physicochemical feature-based local environment learning using transformer","volume":"2","author":"Xue","year":"2025","journal-title":"Npj Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108952_bb0385","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1107\/S2053230X20009243","article-title":"Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313","volume":"76","author":"Talapati","year":"2020","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"10.1016\/j.bioorg.2025.108952_bb0390","doi-asserted-by":"crossref","first-page":"27409","DOI":"10.1039\/D2RA02885A","article-title":"A validated LC-MS\/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes","volume":"12","author":"Attwa","year":"2022","journal-title":"RSC Adv."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:23:04Z","timestamp":1760559784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":78,"alternative-id":["S0045206825008326"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108952","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, biological and computational evaluation of novel S\/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108952"}}